{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:19:09Z","timestamp":1792369149376,"version":"4.4.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Microencapsulation has received extensive attention because of its various applications. Since its inception in the 1940s, this technology has been used across several areas, including the chemical, food, and pharmaceutical industries. Over-the-counter skin products often contain ingredients that readily and unevenly degrade upon contact with the skin. Enclosing these substances within a silica shell can enhance their stability and better regulate their delivery onto and into the skin. Silica microencapsulation uses silica as the matrix material into which ingredients can be embedded to form microcapsules. The FDA recognizes amorphous silica as a safe inorganic excipient and recently approved two new topical therapies for the treatment of rosacea and acne. The first approved formulation uses a novel\u00a0silica-based\u00a0controlled vehicle delivery technology to improve the stability of two active ingredients that are normally not able to be used in the same formulation due to potential instability and drug degradation. The formulation contains 3.0% benzoyl peroxide (BPO) and 0.1% tretinoin topical cream to treat acne vulgaris in adults and pediatric patients. The second formulation contains silica microencapsulated 5.0% BPO topical cream to treat inflammatory rosacea lesions in adults. Both formulations use the same amorphous silica sol\u2013gel microencapsulation technology to improve formulation stability and skin compatibility parameters.<\/jats:p>","DOI":"10.1007\/s00403-023-02725-z","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T10:01:57Z","timestamp":1696413717000},"page":"2787-2793","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Silica-based microencapsulation used in topical dermatologic applications"],"prefix":"10.1007","volume":"315","author":[{"given":"Lawrence J.","family":"Green","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Toledano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Erlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Spizuoco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin C.","family":"Goodyear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Philippe","family":"York","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Jakus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"key":"2725_CR1","doi-asserted-by":"crossref","unstructured":"Trottet L, Maibach H (2017). Key factors affecting the efficacy of a topical drug candidate: learnings from past topical drug development. In: Dermal drug selection and development. Springer, Cham, pp 29\u201338","DOI":"10.1007\/978-3-319-59504-7_3"},{"issue":"1","key":"2725_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/02652048.2015.1115900","volume":"33","author":"F Casanova","year":"2016","unstructured":"Casanova F, Santos L (2016) Encapsulation of cosmetic active ingredients for topical application\u2013\u2013a review. J Microencapsul 33(1):1\u201317","journal-title":"J Microencapsul"},{"key":"2725_CR3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.toxrep.2017.05.006","volume":"4","author":"JA Ruszkiewicz","year":"2017","unstructured":"Ruszkiewicz JA, Pinkas A, Ferrer B et al (2017) Neurotoxic effect of active ingredients in sunscreen products, a contemporary review. Toxicol Rep 4:245\u2013259","journal-title":"Toxicol Rep"},{"issue":"1","key":"2725_CR4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40257-019-00480-4","volume":"21","author":"RM Law","year":"2020","unstructured":"Law RM, Ngo MA, Maibach HI (2020) Twenty clinically pertinent factors\/observations for percutaneous absorption in humans. Am J Clin Dermatol 21(1):85\u201395","journal-title":"Am J Clin Dermatol"},{"key":"2725_CR5","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jcis.2020.06.114","volume":"579","author":"M Erlich","year":"2020","unstructured":"Erlich M, Arie T, Koifman N, Talmon Y (2020) Structure elucidation of silica-based core-shell microencapsulated drugs for topical applications by cryogenic scanning electron microscopy. J Colloid Interface Sci 579:778\u2013785","journal-title":"J Colloid Interface Sci"},{"key":"2725_CR6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fchem.2015.00042","volume":"3","author":"MA Ashraf","year":"2015","unstructured":"Ashraf MA, Khan AM, Ahmad M, Sarfraz M (2015) Effectiveness of silica based sol-gel microencapsulation method for odorants and flavors leading to sustainable environment. Front Chem 3:42","journal-title":"Front Chem"},{"issue":"2","key":"2725_CR7","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1021\/cr100161x","volume":"111","author":"R Ciriminna","year":"2011","unstructured":"Ciriminna R, Sciortino M, Alonzo G, Schrijver A, Pagliaro M (2011) From molecules to systems: sol-gel microencapsulation in silica-based materials. Chem Rev 111(2):765\u2013789","journal-title":"Chem Rev"},{"key":"2725_CR8","doi-asserted-by":"crossref","unstructured":"Ghosh SK (2006) Functional coatings and microencapsulation: a general perspective. In: Functional coatings, pp 1\u201328","DOI":"10.1002\/3527608478.ch1"},{"key":"2725_CR9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/B978-081551504-3.50013-4","volume-title":"Delivery system handbook for personal care and cosmetic products","author":"Z Lidert","year":"2005","unstructured":"Lidert Z (2005) 8\u2014Microencapsulation: an overview of the technology landscape. In: Rosen MR (ed) Delivery system handbook for personal care and cosmetic products. William Andrew Publishing, Norwich, pp 181\u2013190"},{"key":"2725_CR10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/B978-081551504-3.50016-X","volume-title":"Delivery system handbook for personal acre and cosmetic products","author":"T Elder","year":"2005","unstructured":"Elder T, Bell A (2005) Phase-change materials: a novel microencapsulation technique for personal care. In: Rosen MR (ed) Delivery system handbook for personal acre and cosmetic products. William Andrew Publishing, Norwich, pp 259\u2013272"},{"key":"2725_CR11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/B978-081551504-3.50015-8","volume-title":"Delivery system handbook for personal care and cosmetic products","author":"E Kvitnitsky","year":"2005","unstructured":"Kvitnitsky E, Lerner N, Shapiro YE (2005) Tagravit\u2122 microcapsules as controlled drug delivery devices and their formulations. In: Rosen MR (ed) Delivery system handbook for personal care and cosmetic products. William Andrew Publishing, Norwich, pp 215\u2013258"},{"key":"2725_CR12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/978-3-540-49339-6_20","volume-title":"Flavours and fragrances: chemistry, bioprocessing and sustainability","author":"JJG van Soest","year":"2007","unstructured":"van Soest JJG (2007) Encapsulation of fragrances and flavours: a way to control odour and aroma in consumer products. In: Berger RG (ed) Flavours and fragrances: chemistry, bioprocessing and sustainability. Springer, Berlin, pp 439\u2013455"},{"key":"2725_CR13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.lwt.2015.10.062","volume":"66","author":"D Maresca","year":"2016","unstructured":"Maresca D, De Prisco A, La Storia A et al (2016) Microencapsulation of nisin in alginate beads by vibrating technology: preliminary investigation. LWT Food Sci Technol 66:436\u2013443","journal-title":"LWT Food Sci Technol"},{"key":"2725_CR14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.colsurfb.2012.10.059","volume":"103","author":"EC Morais","year":"2013","unstructured":"Morais EC, Correa GG, Brambilla R et al (2013) The interaction of encapsulated pharmaceutical drugs with a silica matrix. Colloids Surf B Biointerfaces 103:422\u2013429","journal-title":"Colloids Surf B Biointerfaces"},{"key":"2725_CR15","first-page":"1","volume":"33","author":"F Bastos","year":"2015","unstructured":"Bastos F, Santos L (2015) Encapsulation of cosmetic active ingredients for topical application\u2014a review. J Microencapsul 33:1\u201317","journal-title":"J Microencapsul"},{"key":"2725_CR16","first-page":"1","volume-title":"The sol-gel handbook","author":"U Schubert","year":"2015","unstructured":"Schubert U (2015) Chemistry and fundamentals of the sol\u2013gel process. In: Levy D, Zayat M (eds) The sol-gel handbook, 1st edn. Wiley-VCH, Weinheim, pp 1\u201328","edition":"1"},{"issue":"5","key":"2725_CR17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1529-8019.2012.01464.x","volume":"24","author":"S Fireman","year":"2011","unstructured":"Fireman S, Toledano O, Neimann K, Loboda N, Dayan N (2011) A look at emerging delivery systems for topical drug products. Dermatol Ther 24(5):477\u2013488","journal-title":"Dermatol Ther"},{"key":"2725_CR18","unstructured":"Levy Hacham O, Toledano O (2020) Characterization of microencapsulated benzoyl peroxide (E-BPO) for the treatment of papulopustular rosacea. dd08da6e-032b-448f-85a2-cc552a22fad9 (sol-gel.com). Accessed 11 Apr 2023"},{"issue":"7","key":"2725_CR19","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.xphs.2016.03.019","volume":"105","author":"CG Abrantes","year":"2016","unstructured":"Abrantes CG, Duarte D, Reis CP (2016) An overview of pharmaceutical excipients: safe or not safe? J Pharm Sci 105(7):2019\u20132026","journal-title":"J Pharm Sci"},{"key":"2725_CR20","unstructured":"United States Pharmacopeia and National Formulary. <1059> EXCIPIENT PERFORMANCE (triphasepharmasolutions.com). Accessed 11 Apr 2023"},{"issue":"10","key":"2725_CR21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s11095-020-02919-4","volume":"37","author":"VA Rao","year":"2020","unstructured":"Rao VA, Kim JJ, Patel DS, Rains K, Estoll CR (2020) A comprehensive scientific survey of excipients used in currently marketed, therapeutic biological drug products. Pharm Res 37(10):200","journal-title":"Pharm Res"},{"issue":"1","key":"2725_CR22","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ejpb.2008.03.019","volume":"70","author":"X Ren","year":"2008","unstructured":"Ren X, Mao X, Si L et al (2008) Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm 70(1):279\u2013288","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"2725_CR23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1208\/s12249-017-0902-2","volume":"19","author":"S Narasimha Murthy","year":"2018","unstructured":"Narasimha Murthy S, Repka MA (2018) Excipient stability: a critical aspect in stability of pharmaceuticals. AAPS PharmSciTech 19(1):11","journal-title":"AAPS PharmSciTech"},{"issue":"483","key":"2725_CR24","doi-asserted-by":"crossref","first-page":"eaau6753","DOI":"10.1126\/scitranslmed.aau6753","volume":"11","author":"D Reker","year":"2019","unstructured":"Reker D, Blum SM, Steiger C et al (2019) \u201cInactive\u201d ingredients in oral medications. Sci Transl Med. 11(483):eaau6753","journal-title":"Sci Transl Med."},{"key":"2725_CR25","unstructured":"Data on file, Sol-Gel Technologies Ltd. Number 03-10-65-122"},{"key":"2725_CR26","unstructured":"Data on file, Sol-Gel Technologies Ltd. Number 03-10-00-38"},{"issue":"1","key":"2725_CR27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1743-7075-10-2","volume":"10","author":"LM Jurki\u0107","year":"2013","unstructured":"Jurki\u0107 LM, Cepanec I, Paveli\u0107 SK, Paveli\u0107 K (2013) Biological and therapeutic effects of ortho-silicic acid and some ortho-silicic acid-releasing compounds: new perspectives for therapy. Nutr Metab (Lond) 10(1):2","journal-title":"Nutr Metab (Lond)"},{"key":"2725_CR28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/978-94-007-7500-8_14","volume":"13","author":"KR Martin","year":"2013","unstructured":"Martin KR (2013) Silicon: the health benefits of a metalloid. Met Ions Life Sci 13:451\u2013473","journal-title":"Met Ions Life Sci"},{"issue":"3","key":"2725_CR29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/cosmetics5030041","volume":"5","author":"AO Ferreira","year":"2018","unstructured":"Ferreira AO, Freire \u00c9S, Polonini HC et al (2018) Anti-aging effects of monomethylsilanetriol and maltodextrin-stabilized orthosilicic acid on nails, skin and hair. Cosmetics 5(3):41","journal-title":"Cosmetics"},{"key":"2725_CR30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/B978-0-444-59550-8.00005-3","volume-title":"Encyclopedia of the alkaline earth compounds","author":"RC Ropp","year":"2013","unstructured":"Ropp RC (2013) Chapter 5-Group 14 (C, Si, Ge, Sn, and Pb) alkaline earth compounds. In: Ropp RC (ed) Encyclopedia of the alkaline earth compounds. Elsevier, Amsterdam, pp 351\u2013480"},{"issue":"3","key":"2725_CR31","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1590\/abd1806-4841.20163986","volume":"91","author":"LA Ara\u00fajo","year":"2016","unstructured":"Ara\u00fajo LA, Addor F, Campos PM (2016) Use of silicon for skin and hair care: an approach of chemical forms available and efficacy. An Bras Dermatol 91(3):331\u2013335","journal-title":"An Bras Dermatol"},{"key":"2725_CR32","unstructured":"United States Department of Labor (2023) Crystalline silica, overview. https:\/\/www.osha.gov\/silica-crystalline. Accessed 6 Apr 2023"},{"key":"2725_CR33","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1747953","author":"S Sarembe","year":"2022","unstructured":"Sarembe S, Ufer C, Kiesow A et al (2022) Influence of the amount of toothpaste on cleaning efficacy: an in vitro study. Eur J Dent. https:\/\/doi.org\/10.1055\/s-0042-1747953","journal-title":"Eur J Dent"},{"key":"2725_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-8977-8-1","volume":"8","author":"H Nabeshi","year":"2011","unstructured":"Nabeshi H, Yoshikawa T, Matsuyama K et al (2011) Amorphous nanosilica induce endocytosis-dependent ROS generation and DNA damage in human keratinocytes. Part Fibre Toxicol 8:1","journal-title":"Part Fibre Toxicol"},{"issue":"3","key":"2725_CR35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092634","volume":"9","author":"T Kusaka","year":"2014","unstructured":"Kusaka T, Nakayama M, Nakamura K et al (2014) Effect of silica particle size on macrophage inflammatory responses. PLoS ONE 9(3):e92634","journal-title":"PLoS ONE"},{"issue":"5","key":"2725_CR36","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3109\/17435390.2014.958115","volume":"9","author":"S Nafisi","year":"2015","unstructured":"Nafisi S, Sch\u00e4fer-Korting M, Maibach HI (2015) Perspectives on percutaneous penetration: Silica nanoparticles. Nanotoxicol 9(5):643\u2013657","journal-title":"Nanotoxicol"},{"issue":"11\u201312","key":"2725_CR37","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s002040100266","volume":"75","author":"R Merget","year":"2002","unstructured":"Merget R, Bauer T, K\u00fcpper HU et al (2002) Health hazards due to the inhalation of amorphous silica. Arch Toxicol 75(11\u201312):625\u2013634","journal-title":"Arch Toxicol"},{"key":"2725_CR38","volume":"151","author":"Y Huang","year":"2022","unstructured":"Huang Y, Li P, Zhao R et al (2022) Silica nanoparticles: biomedical applications and toxicity. Biomed Pharmacother 151:113053","journal-title":"Biomed Pharmacother"},{"key":"2725_CR39","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.2147\/IJN.S383324","volume":"17","author":"JK Choi","year":"2022","unstructured":"Choi JK, Park JY, Lee S et al (2022) Greater plasma protein adsorption on mesoporous silica nanoparticles aggravates atopic dermatitis. Int J Nanomed 17:4599\u20134617","journal-title":"Int J Nanomed"},{"key":"2725_CR40","unstructured":"United States Food and Drug Administration (2023) CFR\u2014Code of Federal Regulations Title 21. Sec 172.480 silicon dioxide. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=172.480. Accessed 6 Apr 2023"},{"key":"2725_CR41","unstructured":"United States Food and Drug Administration (2023) CFR\u2014Code of Federal Regulations Title 21. Sec 584.700 Hydrophobic Silicas. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=584.700. Accessed 6 Apr 2023"},{"key":"2725_CR42","unstructured":"National Archives (2023) Code of Federal Regulations. Title 21. \u00a7 172.480 silicon dioxide. https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-B\/part-172\/subpart-E\/section-172.480. Accessed 6 Apr 2023"},{"issue":"3","key":"2725_CR43","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000354914","volume":"27","author":"K De Paepe","year":"2014","unstructured":"De Paepe K, Sieg A, Le Meur M, Rogiers V (2014) Silicones as nonocclusive topical agents. Skin Pharmacol Physiol 27(3):164\u2013171","journal-title":"Skin Pharmacol Physiol"},{"issue":"3","key":"2725_CR44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0305-4179(83)90039-6","volume":"9","author":"K Perkins","year":"1983","unstructured":"Perkins K, Davey RB, Wallis KA (1983) Silicone gel: a new treatment for burn scars and contractures. Burns Incl Therm Inj 9(3):201\u2013204","journal-title":"Burns Incl Therm Inj"},{"issue":"7","key":"2725_CR45","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1089\/wound.2015.0625","volume":"4","author":"B Bleasdale","year":"2015","unstructured":"Bleasdale B, Finnegan S, Murray K, Kelly S, Percival SL (2015) The use of silicone adhesives for scar reduction. Adv Wound Care (New Rochelle) 4(7):422\u2013430","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"2725_CR46","unstructured":"United States Food and Drug Administration (2023) Inactive ingredient search for approved drug products. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/iig\/index.cfm?event=BasicSearch.page. Accessed 6 Apr 2023"},{"key":"2725_CR47","unstructured":"Galderma Launches EPSOLAY\u00ae Cream (2022) A medical advance to treat bumps and blemishes of Rosacea. https:\/\/ir.sol-gel.com\/news-releases\/news-release-details\/galderma-launches-epsolayr-cream-medical-advance-treat-bumps-and. Accessed 6 Apr 2023"},{"key":"2725_CR48","unstructured":"Sol-Gel Technologies Announces the Commercial Availability of TWYNEO\u00ae 2022. https:\/\/ir.sol-gel.com\/news-releases\/news-release-details\/sol-gel-technologies-announces-commercial-availability-twyneor. Accessed 6 Apr 2023"},{"key":"2725_CR49","unstructured":"The Next Generation in Sun Protection. https:\/\/www.emdgroup.com\/en\/brands\/pm\/eusolex\/eusolex-uv-pearls.html. Accessed 6 Apr 2023"},{"issue":"7","key":"2725_CR50","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/jbm.b.33711","volume":"105","author":"JU Park","year":"2017","unstructured":"Park JU, Jung HD, Song EH et al (2017) The accelerating effect of chitosan-silica hybrid dressing materials on the early phase of wound healing. J Biomed Mater Res B Appl Biomater 105(7):1828\u20131839","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"2725_CR51","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.2147\/IJN.S273062","volume":"16","author":"D \u015een Karaman","year":"2021","unstructured":"\u015een Karaman D, Pamuk\u00e7u A, Karakaplan MB, Kocaoglu O, Rosenholm JM (2021) Recent advances in the use of mesoporous silica nanoparticles for the diagnosis of bacterial infections. Int J Nanomed 16:6575\u20136591","journal-title":"Int J Nanomed"},{"issue":"17","key":"2725_CR52","doi-asserted-by":"crossref","first-page":"14299","DOI":"10.1021\/acsami.7b15678","volume":"10","author":"S Yang","year":"2018","unstructured":"Yang S, Han X, Yang Y et al (2018) Bacteria-targeting nanoparticles with microenvironment-responsive antibiotic release to eliminate intracellular Staphylococcus aureus and associated infection. ACS Appl Mater Interfaces 10(17):14299\u201314311","journal-title":"ACS Appl Mater Interfaces"},{"issue":"5","key":"2725_CR53","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s42247-021-00236-z","volume":"4","author":"HT Trinh","year":"2021","unstructured":"Trinh HT, Mohanan S, Radhakrishnan D et al (2021) Silica-based nanomaterials as drug delivery tools for skin cancer (melanoma) treatment. Emerg Mater 4(5):1067\u20131092","journal-title":"Emerg Mater"},{"issue":"36","key":"2725_CR54","doi-asserted-by":"crossref","first-page":"17041","DOI":"10.1039\/C9NR06303J","volume":"11","author":"DCS Lio","year":"2019","unstructured":"Lio DCS, Liu C, Oo MMS et al (2019) Transdermal delivery of small interfering RNAs with topically applied mesoporous silica nanoparticles for facile skin cancer treatment. Nanoscale 11(36):17041\u201317051","journal-title":"Nanoscale"},{"issue":"1","key":"2725_CR55","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ijpharm.2016.07.024","volume":"511","author":"E Ugazio","year":"2016","unstructured":"Ugazio E, Gastaldi L, Brunella V et al (2016) Thermoresponsive mesoporous silica nanoparticles as a carrier for skin delivery of quercetin. Int J Pharm 511(1):446\u2013454","journal-title":"Int J Pharm"},{"key":"2725_CR56","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.colsurfb.2013.05.027","volume":"111","author":"G Liu","year":"2013","unstructured":"Liu G, Zhu C, Xu J et al (2013) Thermo-responsive hollow silica microgels with controlled drug release properties. Colloids Surf B Biointerfaces 111:7\u201314","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"1","key":"2725_CR57","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5731\/pdajpst.2013.00901","volume":"67","author":"R Dhurke","year":"2013","unstructured":"Dhurke R, Kushwaha I, Desai BG (2013) Improvement in photostability of pantoprazole sodium by microencapsulation. PDA J Pharm Sci Technol 67(1):43\u201352","journal-title":"PDA J Pharm Sci Technol"},{"key":"2725_CR58","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.cis.2017.04.005","volume":"249","author":"R Diab","year":"2017","unstructured":"Diab R, Canilho N, Pavel IA et al (2017) Silica-based systems for oral delivery of drugs, macromolecules and cells. Adv Colloid Interface Sci 249:346\u2013362","journal-title":"Adv Colloid Interface Sci"},{"issue":"2","key":"2725_CR59","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0162-0134(99)00126-9","volume":"76","author":"DM Reffitt","year":"1999","unstructured":"Reffitt DM, Jugdaohsingh R, Thompson RP, Powell JJ (1999) Silicic acid: its gastrointestinal uptake and urinary excretion in man and effects on aluminium excretion. J Inorg Biochem 76(2):141\u2013147","journal-title":"J Inorg Biochem"},{"issue":"4","key":"2725_CR60","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.3390\/ijms22041896","volume":"22","author":"T Christoforidou","year":"2021","unstructured":"Christoforidou T, Giasafaki D, Andriotis EG et al (2021) Oral drug delivery systems based on ordered mesoporous silica nanoparticles for modulating the release of aprepitant. Int J Mol Sci 22(4):1896","journal-title":"Int J Mol Sci"},{"key":"2725_CR61","volume":"10","author":"Z Li","year":"2022","unstructured":"Li Z, Guo J, Zhang M, Li G, Hao L (2022) Gadolinium-coated mesoporous silica nanoparticle for magnetic resonance imaging. Front Chem 10:837032","journal-title":"Front Chem"},{"issue":"105","key":"2725_CR62","doi-asserted-by":"crossref","first-page":"61160","DOI":"10.1039\/C4RA12973C","volume":"4","author":"RJ Mudakavi","year":"2014","unstructured":"Mudakavi RJ, Raichur AM, Chakravortty D (2014) Lipid coated mesoporous silica nanoparticles as an oral delivery system for targeting and treatment of intravacuolar Salmonella infections. RSC Adv 4(105):61160\u201361166","journal-title":"RSC Adv"},{"issue":"12","key":"2725_CR63","doi-asserted-by":"crossref","first-page":"11936","DOI":"10.1021\/acsnano.8b03007","volume":"12","author":"HP Tham","year":"2018","unstructured":"Tham HP, Xu K, Lim WQ et al (2018) Microneedle-assisted topical delivery of photodynamically active mesoporous formulation for combination therapy of deep-seated melanoma. ACS Nano 12(12):11936\u201311948","journal-title":"ACS Nano"},{"issue":"4","key":"2725_CR64","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1080\/03639045.2016.1275668","volume":"43","author":"M Karimzadeh","year":"2017","unstructured":"Karimzadeh M, Rashidi L, Ganji F (2017) Mesoporous silica nanoparticles for efficient rivastigmine hydrogen tartrate delivery into SY5Y cells. Drug Dev Ind Pharm 43(4):628\u2013636","journal-title":"Drug Dev Ind Pharm"},{"issue":"11","key":"2725_CR65","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.1021\/acsami.5b11730","volume":"8","author":"J Mo","year":"2016","unstructured":"Mo J, He L, Ma B, Chen T (2016) Tailoring particle size of mesoporous silica nanosystem to antagonize glioblastoma and overcome blood\u2013brain barrier. ACS Appl Mater Interfaces 8(11):6811\u20136825","journal-title":"ACS Appl Mater Interfaces"},{"issue":"8","key":"2725_CR66","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s11095-017-2177-4","volume":"34","author":"J Tu","year":"2017","unstructured":"Tu J, Du G, Reza Nejadnik M et al (2017) Mesoporous silica nanoparticle-coated microneedle arrays for intradermal antigen delivery. Pharm Res 34(8):1693\u20131706","journal-title":"Pharm Res"},{"issue":"1","key":"2725_CR67","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13756-020-00813-7","volume":"9","author":"M Scotoni","year":"2020","unstructured":"Scotoni M, Koch J, Julian TR et al (2020) Silica nanoparticles with encapsulated DNA (SPED)\u2014a novel surrogate tracer for microbial transmission in healthcare. Antimicrob Resist Infect Control 9(1):152","journal-title":"Antimicrob Resist Infect Control"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-023-02725-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-023-02725-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-023-02725-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T07:06:26Z","timestamp":1698649586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-023-02725-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":67,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2725"],"URL":"https:\/\/doi.org\/10.1007\/s00403-023-02725-z","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,4]]},"assertion":[{"value":"31 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LJG is an investigator, speaker, or consultant to: Abbvie, Alumis, Arcutis, Amgen, BMS, Cara, Dermavant, DermTech, Highlittl, Janssen, Lilly, Novan, OrthoDerm, SunPharma, Takeda, UCB, Ventyx, Verrica. NDB is an advisor, consultant, and investigator for Galderma and Sol-Gel Technologies.  OT and ME are employees of Sol-Gel Technologies.  AS is a speaker for Diversity in Dermatology and the American Osteopathic College of Dermatology; had employment or consultation with Amgen, Ortho Dermatologics, Galderma, Regeneron\/Sanofi, BMS, Arcutis, Dermavant, Eli Lilly, CeraVe, Verrica; and had a position on advisory board or board of directors or other type of management relationships with: Amgen, Ortho Dermatologics, Galderma, Regeneron\/Sanofi, BMS, Arcutis, Dermavant, Eli Lilly, CeraVe, and Verrica. BCG and JPY are employees of Galderma Laboratories.  JJ is an investigator in Galderma clinical trials unrelated to the subject matter of this manuscript. She is an investigator and speaker for other companies, none of which represent a conflict of interest for this publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"LJG is an investigator, speaker, or consultant\u00a0to: Abbvie, Alumis,\u00a0Arcutis, Amgen, BMS, Cara, Dermavant, DermTech, Highlittl, Janssen, Lilly, Novan, OrthoDerm, SunPharma, Takeda, UCB, Ventyx, Verrica. NDB is an advisor, consultant, and investigator for Galderma and Sol\u2013Gel Technologies. OT and ME are employees of Sol\u2013Gel Technologies. AS is a speaker for Diversity in Dermatology and the American Osteopathic College of Dermatology; had employment or consultation with Amgen, Ortho Dermatologics, Galderma, Regeneron\/Sanofi, BMS, Arcutis, Dermavant, Eli Lilly, CeraVe, Verrica; and had a position on advisory board or board of directors or other type of management relationships with: Amgen, Ortho Dermatologics, Galderma, Regeneron\/Sanofi, BMS, Arcutis, Dermavant, Eli Lilly, CeraVe, and Verrica. BCG and JPY are employees of Galderma Laboratories. JJ is an investigator in Galderma clinical trials unrelated to the subject matter of this manuscript. She is an investigator and speaker for other companies, none of which represent a conflict of interest for this publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}